CSF1R and non-small cell lung carcinoma: Combining the anti-CSF-1R with ICI in murine models led to significant tumor reduction (106), however, systemic depletion of macrophages either causes undesired side effects (107) or insufficient antitumor response in NSCLC patients (108, 109).